• 57613 Citations
1976 …2023
If you made any changes in Pure, your changes will be visible here soon.

Personal profile

Research Interests

I have been an active clinical investigator vested in the immune-based therapy of melanoma. This has led to my role in the clinical development of initially Interleukin-2 and more recently anti-CTLA-4 and anti-PD1/PDL-1. While checkpoint therapy has been a great breakthrough in cancer treatment, additional immune-based strategies are still critically needed. Efforts to identify mechanisms of resistance to checkpoint inhibitors and approaches to overcome de novo and acquired resistance are one of my major interest. In addition I have ongoing efforts in the personalized therapy of melanoma with well-defined targets (BRAF v600, NRAS mutations, CKIT mutations). I co-lead the Northwestern Cancer Center Translational Research in Solid Tumors (TRIST) program which is critical to the success of the Cancer Center. In this role, I am working to bring translational studies including immunotherapy based trials to all solid tumors. The development of translational studies that will provide a better understanding to sensitivity and resistance to both immune checkpoint therapy and targeted therapy is my highest priority. As Co-Leader of TRIST program, I am determined to bring creative immune based trials to cancers .

Training Experience

1982Internship, University of Chicago Hospitals
1985Residency, University of Chicago Hospitals
1986Residency, University of Wisconsin Hospital & Clinics
1989Fellowship, University of Wisconsin Hospital & Clinics

Education/Academic qualification

MD, Albert Einstein College

… → 1981

Keywords

  • Genomic Medicine/Personalized Medicine
  • Immunology
  • Kidney Cancer / Urinary Tract Cancer
  • Skin Cancer

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

Melanoma Medicine & Life Sciences
Interleukin-2 Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Renal Cell Carcinoma Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Immunotherapy Medicine & Life Sciences
Survival Medicine & Life Sciences
Mutation Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants 2011 2023

Colitis
Melanoma
Allergy and Immunology
Immunotherapy
T-Lymphocytes

Research Output 1976 2019

Adverse Events Associated with Immune Checkpoint Inhibitors - Reply

Johnson, D. B., Chandra, S. & Sosman, J. A., Mar 26 2019, In : JAMA - Journal of the American Medical Association. 321, 12, p. 1219-1220 2 p.

Research output: Contribution to journalLetter

CD73 expression on effector T cells sustained by TGF-β facilitates tumor resistance to anti-4-1BB/CD137 therapy

Chen, S., Fan, J., Zhang, M., Qin, L., Dominguez, D., Long, A., Wang, G., Ma, R., Li, H., Zhang, Y., Fang, D., Sosman, J. A. & Zhang, B., Dec 1 2019, In : Nature communications. 10, 1, 150.

Research output: Contribution to journalArticle

effectors
T-cells
Tumors
therapy
tumors

Clinical characterization of colitis arising from anti-PD-1 based therapy

Wang, D. Y., Mooradian, M. J., Kim, D. W., Shah, N. J., Fenton, S. E., Conry, R. M., Mehta, R., Silk, A. W., Zhou, A., Compton, M. L., Al-Rohil, R. N., Lee, S., Voorhees, A. L., Ha, L., McKee, S., Norrell, J. T., Mehnert, J., Puzanov, I., Sosman, J. A., Chandra, S. & 5 othersGibney, G. T., Rapisuwon, S., Eroglu, Z., Sullivan, R. & Johnson, D. B., Jan 2 2019, In : OncoImmunology. 8, 1, e1524695.

Research output: Contribution to journalArticle

Colitis
Steroids
Therapeutics
Prednisone
Melanoma

Clinical Correlates of Response to Anti-PD-1-based Therapy in Patients with Metastatic Melanoma

Davis, E. J., Perez, M. C., Ayoubi, N., Zhao, S., Ye, F., Wang, D. Y., Sosman, J. A., Al-Rohil, R. N., Eroglu, Z. & Johnson, D. B., Jan 1 2019, In : Journal of Immunotherapy.

Research output: Contribution to journalArticle

Melanoma
Neoplasms
Neoplasm Metastasis
Disease-Free Survival
Therapeutics

Hybrid Capture-Based Genomic Profiling Identifies BRAF V600 and Non-V600 Alterations in Melanoma Samples Negative by Prior Testing

Boussemart, L., Nelson, A., Wong, M., Ross, J. S., Sosman, J. A., Mehnert, J., Daniels, G., Kendra, K., Ali, S. M., Miller, V. A. & Schrock, A. B., Jan 1 2019, (Accepted/In press) In : Oncologist.

Research output: Contribution to journalArticle

Melanoma
Mitogen-Activated Protein Kinase Kinases
Mutation
Practice Guidelines
Patient Selection